Evidence map›Paper›PMID 39865733›Full record

ArticleBrain : a journal of neurology2025

Multiomic analyses direct hypotheses for Creutzfeldt-Jakob disease risk genes.

Fahri Küçükali, Elizabeth Hill, Tijs Watzeels, Holger Hummerich, Tracy Campbell, Lee Darwent, Steven Collins, Christiane Stehmann, Gabor G Kovacs, Michael D Geschwind and 33 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. DNA methylation as a contributor to dysregulation ofbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Fahri KüçükaliComplex Genetics of Alzheimer's Disease group, VIB Center for Molecular Neurology, VIB, Antwerp 2610, Belgium.
Elizabeth HillMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.
Tijs WatzeelsComplex Genetics of Alzheimer's Disease group, VIB Center for Molecular Neurology, VIB, Antwerp 2610, Belgium.
Holger HummerichMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.
Tracy CampbellMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.
Lee DarwentMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.
Steven CollinsAustralian National Creutzfeldt-Jakob Disease Registry, The Florey and Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria 3010, Australia.
Christiane StehmannAustralian National Creutzfeldt-Jakob Disease Registry, The Florey and Department of Medicine (RMH), The University of Melbourne, Melbourne, Victoria 3010, Australia.
Gabor G KovacsDepartment of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0003-3841-5511
Michael D GeschwindUCSF Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158, USA.
Karl FrontzekInstitute of Neuropathology, University of Zürich, 8006 Zürich, Switzerland.
Herbert BudkaAustrian Reference Centre for Human Prion Diseases, Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University Vienna, 1090 Vienna, Austria.
Ellen GelpiAustrian Reference Centre for Human Prion Diseases, Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University Vienna, 1090 Vienna, Austria.
Adriano AguzziInstitute of Neuropathology, University of Zürich, 8006 Zürich, Switzerland.
Sven J van der LeeGenomics of Neurodegenerative Diseases and Aging, Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands.
Cornelia M van DuijnDepartment of Epidemiology, Erasmus Medical Centre, 3000 CA Rotterdam, The Netherlands.ORCID 0000-0002-2374-9204
Pawel P LiberskiDepartment of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz 92-215, Poland.
Miguel CaleroChronic Disease Programme (UFIEC) and Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid 28029, Spain.
Pascual Sanchez-JuanReina Sofia Alzheimer Center, CIEN Foundation, ISCIII, Madrid, Spain.ORCID 0000-0002-6081-8037
Elodie Bouaziz-AmarDepartment of Biochemistry and Molecular Biology, Lariboisière Hospital, GHU AP-HP Nord, University of Paris Cité, Paris, France.
Jean-Louis LaplancheDepartment of Biochemistry and Molecular Biology, Lariboisière Hospital, GHU AP-HP Nord, University of Paris Cité, Paris, France.
Stéphane HaïkSorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris 75010, France.
Jean-Phillipe BrandelSorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris 75010, France.
Angela MammanaIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna 40139, Italy.
Sabina CapellariIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna 40139, Italy.ORCID 0000-0003-1631-1439
Anna PoleggiDepartment of Neuroscience, Istituto Superiore di Sanità, Roma 00161, Italy.
Anna LadoganaDepartment of Neuroscience, Istituto Superiore di Sanità, Roma 00161, Italy.
Dorina TipleDepartment of Neuroscience, Istituto Superiore di Sanità, Roma 00161, Italy.
Saima ZafarUniversity Medical Center Göttingen, Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, 37075 Göttingen, Germany.
Stephanie BoothPrion Disease Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E 3R2, Canada.
Gerard H JansenDepartment of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Aušrinė AreškevičiūtėDanish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.
Eva Løbner LundDanish Reference Center for Prion Diseases, Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.
Katie GlisicNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Piero ParchiIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna 40139, Italy.ORCID 0000-0002-9444-9524
Peter HermannUniversity Medical Center Göttingen, Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, 37075 Göttingen, Germany.
Inga ZerrUniversity Medical Center Göttingen, Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, 37075 Göttingen, Germany.
Jiri SafarNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Pierluigi GambettiNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Brian S ApplebyNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 44106, USA.
John CollingeMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.
Kristel SleegersComplex Genetics of Alzheimer's Disease group, VIB Center for Molecular Neurology, VIB, Antwerp 2610, Belgium.
Simon MeadMedical Research Council Prion Unit, University College London Institute of Prion Diseases, London W1W 7FF, UK.

Funding

Topographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomicsU19AG060909 · NIA · ALLEN INSTITUTE · PI Jennie Leigh Close · 2020 to 2026
$83.6M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI Richard B. LIPTON · 1985 to 2026
$73.9M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's DiseaseU01AG046170 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, MINGHUI, ZHANG, BIN · 2013 to 2022
$26.0M
Brein InstituutMedical Research CouncilNational Institute for Health and Care Research BOF 49758NCEZID CDC HHS U51 CK000100NIA NIH HHS P01 AG003949NIA NIH HHS P01 AG017216NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG072975NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG025711NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG018023NIA NIH HHS R01 AG032990NIA NIH HHS R01 AG036836NIA NIH HHS RF1 AG057440NIA NIH HHS U01 AG006781NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG046139NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG046170NIA NIH HHS U01 AG061356NIA NIH HHS U19 AG060909NIA NIH HHS U19 AG066567NIA NIH HHS U24 AG061340NINDS NIH HHS R01 NS074317NINDS NIH HHS R01 NS080820NINDS NIH HHS R01 NS103848NINDS NIH HHS U24 NS072026University of Antwerp
6 · The paper itself

Abstract

Prions are assemblies of misfolded prion protein that cause several fatal and transmissible neurodegenerative diseases, with the most common phenotype in humans being sporadic Creutzfeldt-Jakob disease (sCJD). Aside from variation of the prion protein itself, molecular risk factors are not well understood. Prion and prion-like mechanisms are thought to underpin common neurodegenerative disorders meaning that the elucidation of mechanisms could have broad relevance. Herein we sought to further develop our understanding of the factors that confer risk of sCJD using a systematic gene prioritization and functional interpretation pipeline based on multiomic integrative analyses. We integrated the published sCJD genome-wide association study summary statistics with publicly available bulk brain and brain cell type gene and protein expression datasets. We performed multiple transcriptome and proteome-wide association studies and Bayesian genetic colocalization analyses between sCJD risk association signals and multiple brain molecular quantitative trait loci signals. We then applied our systematic gene prioritization pipeline to the obtained results and nominated prioritized sCJD risk genes with risk-associated molecular mechanisms in a transcriptome and proteome-wide manner. Genetic upregulation of both gene and protein expression of syntaxin-6 (STX6) in the brain was associated with sCJD risk in multiple datasets, with a risk-associated gene expression regulation specific to oligodendrocytes. Similarly, increased gene and protein expression of protein disulfide isomerase family A member 4 (PDIA4), involved in the unfolded protein response, was linked to increased disease risk, particularly in excitatory neurons. Protein expression of mesencephalic astrocyte derived neurotrophic factor (MANF), involved in protection against endoplasmic reticulum stress and sulfatide binding (linking to the enzyme in the final step of sulfatide synthesis, encoded by sCJD risk gene GAL3ST1), was identified as protective against sCJD. In total 32 genes were prioritized into two tiers based on the level of evidence and confidence for further studies. This study provides insights into the genetically-associated molecular mechanisms underlying sCJD susceptibility and prioritizes several specific hypotheses for exploration beyond the prion protein itself, as well as beyond the previously highlighted sCJD risk loci, through the newly prioritized sCJD risk genes and mechanisms. These findings highlight the importance of glial cells, sulfatides and the excitatory neuron unfolded protein response in sCJD pathogenesis.

Indexed as

Creutzfeldt-Jakob SyndromeGenetic Predisposition to DiseaseBrainGenome-Wide Association StudyHumansRisk FactorsTranscriptomemultiomicsneurodegenerationproteome-wide association studies (PWAS)sporadic Creutzfeldt-Jakob disease (sCJD)transcriptome-wide association studies (TWAS)

Identifiers

PMID39865733
PMCPMC12404779

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.